Barrington Research Issues Positive Forecast for Option Care Health (NASDAQ:OPCH) Stock Price

Option Care Health (NASDAQ:OPCH) had its price target hoisted by Barrington Research from $38.00 to $42.00 in a report released on Friday, Marketbeat Ratings reports. Barrington Research currently has an outperform rating on the stock.

Several other equities research analysts have also recently weighed in on OPCH. Citigroup reiterated an “outperform” rating on shares of Option Care Health in a research report on Tuesday. Morgan Stanley upped their target price on shares of Option Care Health from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday. Citizens Jmp reissued a “market outperform” rating and issued a $38.00 price target (up from $36.00) on shares of Option Care Health in a report on Tuesday. Truist Financial set a $40.00 price target on shares of Option Care Health in a report on Tuesday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Option Care Health in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.50.

Option Care Health Trading Down 0.2%

Shares of OPCH stock opened at $36.03 on Friday. The stock has a market capitalization of $5.72 billion, a price-to-earnings ratio of 28.60, a PEG ratio of 2.15 and a beta of 0.80. The company’s fifty day simple moving average is $31.50 and its two-hundred day simple moving average is $29.53. Option Care Health has a 1 year low of $24.24 and a 1 year high of $36.32. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.56 and a quick ratio of 1.05.

Insider Transactions at Option Care Health

In other news, Director Harry M. Jansen Kraemer, Jr. bought 38,000 shares of Option Care Health stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average price of $25.98 per share, with a total value of $987,240.00. Following the completion of the purchase, the director directly owned 413,390 shares in the company, valued at $10,739,872.20. The trade was a 10.12% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.64% of the company’s stock.

Hedge Funds Weigh In On Option Care Health

Several institutional investors have recently modified their holdings of the company. USA Financial Formulas purchased a new position in shares of Option Care Health during the 2nd quarter valued at about $26,000. Cornerstone Planning Group LLC raised its stake in shares of Option Care Health by 7,621.4% during the third quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock worth $30,000 after acquiring an additional 1,067 shares in the last quarter. McIlrath & Eck LLC bought a new stake in shares of Option Care Health in the 2nd quarter worth approximately $37,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Option Care Health in the 2nd quarter worth approximately $40,000. Finally, Advisory Services Network LLC purchased a new stake in shares of Option Care Health in the 3rd quarter valued at $35,000. 98.05% of the stock is currently owned by institutional investors.

Option Care Health Company Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.